Daubert Melissa A, Massaro Joseph, Liao Lawrence, Pershad Ashish, Mulukutla Suresh, Magnus Ohman Erik, Popma Jeffrey, O'Neill William W, Douglas Pamela S
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
Harvard Clinical Research Institute, Boston, MA; Boston University, Boston, MA.
Am Heart J. 2015 Sep;170(3):550-8. doi: 10.1016/j.ahj.2015.06.013. Epub 2015 Jun 26.
Therapies that reverse pathologic left ventricular (LV) remodeling are often associated with improved outcomes. The incidence and impact of reverse LV remodeling after high-risk percutaneous coronary intervention (PCI) are unknown.
The PROTECT II study was a multicenter trial in patients with complex, multivessel coronary artery disease and reduced ejection fraction (EF) that revealed an increase in visual EF after high-risk PCI. Among patients with quantitative echocardiography (LV volumes and biplane EF), we assessed the extent and predictors of reverse LV remodeling, defined as improved systolic function with an absolute increase in EF ≥5% and correlated these findings with clinical events.
Quantitative echocardiography was performed in 184 patients at baseline and longest follow-up. Mean EF at baseline was 27.1%. Ninety-three patients (51%) demonstrated reverse LV remodeling with an absolute increase in EF of 13.2% (P < .001). End-systolic volume decreased from 137.7 to 106.6 mL (P = .002). No significant change in EF or end-systolic volume was seen among non-remodelers. Reverse LV remodeling occurred more frequently in patients with more extensive revascularization (odds ratio, 7.52; 95% CI [1.31-43.25]) and was associated with significantly fewer major adverse events (composite of death/myocardial infarction/stroke/transient ischemic attack): 9.7% versus 24.2% (P = .009). There was also a greater reduction in New York Heart Association class III/IV heart failure among reverse LV remodelers (66.7% to 24.0%) than non-remodelers (56.3% to 34.4%), P = .045.
Reverse LV remodeling can occur after high-risk PCI in patients with complex coronary artery disease and reduced EF and is associated with improved clinical outcomes.
能够逆转病理性左心室(LV)重构的治疗方法通常与改善预后相关。高危经皮冠状动脉介入治疗(PCI)后左心室逆向重构的发生率及影响尚不清楚。
PROTECT II研究是一项针对患有复杂多支冠状动脉疾病且射血分数(EF)降低患者的多中心试验,该试验显示高危PCI后视觉上的EF有所增加。在接受定量超声心动图检查(左心室容积和双平面EF)的患者中,我们评估了左心室逆向重构的程度及预测因素,将其定义为收缩功能改善且EF绝对值增加≥5%,并将这些结果与临床事件相关联。
184例患者在基线期和最长随访期接受了定量超声心动图检查。基线期平均EF为27.1%。93例患者(51%)出现左心室逆向重构,EF绝对值增加13.2%(P <.001)。收缩末期容积从137.7 mL降至106.6 mL(P =.002)。未发生重构的患者中EF或收缩末期容积无显著变化。左心室逆向重构在血管重建更广泛的患者中更频繁发生(优势比,7.52;95% CI [1.31 - 43.25]),且与显著更少的主要不良事件(死亡/心肌梗死/中风/短暂性脑缺血发作的复合事件)相关:9.7% 对比24.2%(P =.009)。左心室逆向重构者中纽约心脏协会III/IV级心力衰竭的减少幅度也大于未发生重构者(从66.7%降至24.0%对比从从56.3%降至34.4%),P =.045。
复杂冠状动脉疾病且EF降低的患者在接受高危PCI后可发生左心室逆向重构,且与临床预后改善相关。